NasdaqGM - Delayed Quote USD

XOMA Corporation (XOMAO)

25.23

+0.05

(+0.20%)

At close: June 20 at 4:00 PM EDT

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B

GlobeNewswire 18 hours ago

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. “OJEMDA™ offers patients six months of age and older who have relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG) the only approved th

GlobeNewswire 8 days ago

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
3 Crazy Good Stocks to Buy With $500 Right Now

Although there was a time when the stock market was solely the playground of the wealthy, it no longer takes money to make money on Wall Street. The democratization of investing means even those with only a few dollars to spare can start building a retirement nest egg — and it won’t even cost you anything to buy and sell shares. The elimination of transaction fees has leveled the playing field for all. So, if you only have a little money available and have already set aside enough for bills and

InvestorPlace 8 days ago

XOMA

RGTIW
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET. The presentation can be accessed at https://bit.l

GlobeNewswire last month

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss

Comprehensive Analysis of XOMA's Financial Performance and Strategic Highlights

GuruFocus.com last month

XOMA
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA’s balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well

GlobeNewswire last month

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
Certara, Inc. (CERT) Q1 Earnings Meet Estimates

Certara (CERT) delivered earnings and revenue surprises of 0% and 2.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CERT

XOMA
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

XOMA
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene®, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder Bayer HealthCare

GlobeNewswire last month

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
$XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)$

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’

GlobeNewswire last month

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
Actym Therapeutics Appoints Thomas Smart as CEO

Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval

PR Newswire last month

PGEN

ANAB

XOMA
XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

Simply Wall St. last month

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
XOMA Corporation Announces Closing of Tender Offer

Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value RightEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KN

GlobeNewswire 2 months ago

KNTE

XOMA

XOMAO
+0.20%
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolioEMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (“Kinnate”; Nasdaq: KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share

GlobeNewswire 3 months ago

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023

Key Financial Highlights and Upcoming Events Set to Influence Future Growth

GuruFocus.com 3 months ago

XOMA
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing royalty base and the achievement of certain development milestones during 2023 Added third commercial asset to XOMA’s portfolio with the acquisition of economic interests in DSUVIA® (sufentanil sublingual tablet) in January 2024 Closed 2023 with two partners’ New Drug Applications (ND

GlobeNewswire 3 months ago

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
XOMA to Present at Upcoming Investor Conferences in March

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences: The 44th Annual TD Cowen Health Care Conference taking place March 4-6, 2024, in Boston, MA. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat on Wednesday, March 6, 2024, at 10:30 AM ET. The presentati

GlobeNewswire 3 months ago

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolioEMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with th

GlobeNewswire 4 months ago

XOMA

XOMAO
+0.20%
XOMAP
+0.39%
With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

Key Insights Significantly high institutional ownership implies XOMA's stock price is sensitive to their trading...

Simply Wall St. 4 months ago

XOMA
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of Defense purchases XOMA is entitled to no less than 50% of the potential $116.5 million in milestone payments EMERYVILLE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has acquired an economic interest in DSUVIA® (sufentanil sublingual tablet)

GlobeNewswire 4 months ago

XOMA

XOMAO
+0.20%
XOMAP
+0.39%

Performance Overview

Return	XOMAO	S&P 500
YTD	+4.70%	+14.75%
1-Year	+16.44%	+24.12%
3-Year	+31.77%	+31.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

XOMA Corporation (XOMAO)

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

3 Crazy Good Stocks to Buy With $500 Right Now

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Certara, Inc. (CERT) Q1 Earnings Meet Estimates

Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Actym Therapeutics Appoints Thomas Smart as CEO

XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years

XOMA Corporation Announces Closing of Tender Offer

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

XOMA to Present at Upcoming Investor Conferences in March

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Performance Overview